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A B S T R A C T
The aim of this study based on an analysis of personal material was to establish stage migration in a relatively
large number of patients who had undergone radical retropubic ascendant prostatectomy (RRP). Between 01.07.1993.
and 31.06.2003. RRP was performed in 801 patients at the urology department of the Kliniken-Essen-Mitte. Data re-
garding diagnostic workup, treatment and postoperative course were collected prospectively into a database. An analy-
sis was made regarding clinical and pathological stage and numbers of patients with positive lymph nodes. During the
observation period the number of radical prostatectomies increased significantly from 8 in 1993 to 130 in 2002. The
number of organ-confined tumors increased continuously between 1997 and 2003. In contrast to this, advanced and
metastatic tumors showed a continuous decrease from 76% in 1997 to 66% in 2002. Between 1994 and 2003 the num-
ber of T1c tumors increased by 20%. Introduction of systematic 12-cylinder biopsy (S12C) increased the detection of
prostatic carcinoma by 38% and the number of diagnosed tumors of a lower clinical stage increased. These facts con-
firm a trend towards clinical and pathological stage migration resulting from extensive use of prostate specific antigen
(PSA) and S12C biopsy in the diagnosis of prostatic carcinoma.
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Introduction
More extensive use of prostate specific antigen
(PSA), ultrasound-guided prostate biopsy and the intro-
duction of anatomically oriented radical retropubic
prostatectomy (RRP), have resulted in a considerable
quantitative increase in diagnosed prostatic carcinoma
and in the number of radical prostatectomies perform-
ed1. Data from the USA, the Netherlands, Switzerland
and Austria show that early detection of prostatic carci-
noma through, PSA-screening is clearly associated with
stage migration towards clinically nonmanifest tum-
or2–6.
Diagnosis of prostatic carcinoma is usually made by
patients referring urologists, by means of laboratory
and ultrasound studies and biopsy of the prostate.
In Germany treatment of non-metastatic, organ-con-
fined prostatic carcinoma in patients of appropriate age
is usually operative.
The aim of this study was to establish possible mi-
gration of clinical and pathological stage on the basis of
an analysis of personal material on a relatively large
number of patients who had undergone RRP during a
ten-year period.
Subjects and Methods
Between July 1, 1993 and June 31, 2003, 801 patient
underwent RRP at the urology department of the Klini-
ken Essen-Mitte. Demographic and descriptive data on
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diagnostic workup, treatment and postoperative course
were collected prospectively in database. In addition to
demographic data, the following information was also
collected: PSA values during the last 10 years, clinical
stage, tumor grading, pathohistological stage and num-
bers of patients with positive lymph nodes. Apart from
this, the preoperative workup included bone scintigra-
phy, CT and prostate biopsy. Parameters are presented
as frequency, mean  standard deviation or median, Q1,
Q3 depending on scale. Time effects were tested for sta-
tistical significance by the Cochran-Mantel-Haenszel or
U-test. All p-values are presented descriptively with no
respect to multiple testing. Statistical analyses were
performed by SAS®.
Results
The urology department of the Kliniken Essen-Mitte
is one of four urology departments in the city of Essen,
the seventh largest town in Germany and the second
largest in the Ruhr region (5.5 million inhabitants). Be-
tween July 1, 1993 and June 31, 2003, 801 patients of
the department underwent radical retropubic ascen-
dent prostatectomy (RRP). The sharp increase in the
number of patients treated between 1993 and 2003 is
shown in Figure 1.
In 1993 operations were performed in 8 patients, in
2002 in 129 patients and in 2003 (up to June 30) in 75
patients. Most of these patients were in the age group
61–70, with almost equal numbers in the groups 51–60
and 71–80. Patients younger than 50 and older than 80
were the exception (Figure 2).
The lowest PSA value was 0.1 ng/ml and the highest
140 ng/ml. The mean PSA was 14.8 ng/ml, the median
9.2 ng/ml. In the years between 1993 and 1999 (except
for 1997) a continuous decrease in the median PSA from
13.8 to 10 ng/ml was registred. From 2000 onwards the
median PSA was about 8 ng/ml.
Although the Wilcoxon test on parallel PSA values
does not show any differences, an increase in the num-
ber of patients with low PSA values was observed dur-
ing the years. In 1996 the number of patients with
PSA<10 ng/ml had increased by 15% and by 2002 it had
increased by 20% (p<0.01) (Figure 3).
The clinical stages of patients operated on are shown
shown in Figure 4 by year of diagnosis. A continuous in-
crease in the number of cT3 tumors was registered be-
tween 1994 and 1998, after which a declining trend fol-
lowed. A similar increase in the number of cT2 tumors
was registered starting from 1994, reaching a maximum
in 2002 and then falling again. The number of prostatic
carcinomas diagnosed by transuretral resection (cT1a
and c T1b) in the period from 1994–1999 changed from
1.5 to 11.1%. From 2000 onwards there was a continu-
ous decrease in tumors detected in this way to 1 %. On
the other hand, from 1994 to 2003 an increase in T1c tu-
mors from 22.2 to 43% was noted.
In the preoperative diagnostic workups CT was per-
formed in 69–90% of patients between 1994 and 2000
and in 37–44.7% between 2001 and 2003. The figures
for bone scintigraphy are similar. Up to 2001 more than
90% of patients had bone scintigraphy before radical
prostatectomy, and from 2001–2003 the number amo-
unted to between 77 and 94%.
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Fig. 4. Distribution of clinical stage (cT) of operated patients per
year (1993–2003).
Before diagnosis patients had an average of two biop-
sies (range 1–3). Ultrasound-guided transrectal biopsy
was performed in all cases.
Reliable information about the number of samples
taken during biopsy exist since 1998.
At that time an average of 3 biopsy samples were
taken (median-3, mean-3.5).
In the following years, precisely every second year,
there was a statistically significant increase in the num-
ber of cylinders taken (p < 0.01). So, from 2001–2003 11
to 12 cylinders were taken from 75% of patients. When
the department introduced a systematic ultrasound
guided biopsy (S12C) the quantity of such operations in-
creased here. Another result was a 38% better detection
of prostatic carcinoma in relation to a traditional sex-
tant (S6C) biopsy.
Migrations of tumor grading between 1993–1997 is
shown in Figure 5. The increase in G1 is evident, with a
peak of 30% in 1995, followed by a decrease.
Since the Gleason score was introduced in 1997, the
changes from that time are shown in Figure 6. So, in
2000 one can observe a 50% increase in Gleason score
2–4, followed by a downward trend. Significant differ-
ences between years are also noticeable.
The distribution of pathohistologic stages by years is
shown in Figure 7. Between 1993–1996 a large number
of organ-limited tumors can be seen. While in 1997 the
number of advanced tumors suddenly decreases by 80%,
the following years show an increase in organ-confined
tumors culminating in 65% in 2003.
Up to 1997 the number of patients with positive
lymph nodes varied between 6% and 18.5%. In 1998
there was an inexplicable increase to 24% and in the
first half of 2003 positive lymph nodes were only ob-
served in 1.3% of patients. The frequency of diagnosing
of affected lymph nodes in relation to preoperative PSA
is shown in Table 1. Positive lymph nodes appeared only
in 2 patients (3.0%) with PSA<4. On the other hand, in
the group of patients with PSA between 4 and 10 ng/ml
lymph nodes were affected in 20.7% in 1998 and in 1.3%
in the first half of 2003.
The incidence of positive lymph nodes in PSA-groups
10.1–20 changed from 23% in 1994 to 0% in the first half
of 2003. Examination of lymph node specimens in patients
with PSA > 20 ng/ml showed positive findings between
50% (1993) and 0% (first half of 2003).
Larger numbers of patients treated with hormonal
therapy were noted in 1996, 1998 and 2003. This is a re-
sult of larger numbers of patients with clinically mani-
fest and locally advanced tumors in these three years.
Patients who had received previous hormone treat-
ment showed statistically significantly higher PSA val-
ues (p = 0.04, Table 2).
Discussion
Broader application of PSA, ultrasound-guided pros-
tate biopsy and intensified public education of the popu-
lation about the problem of prostatic carcinoma, has led
to a significant increase in newly detected tumors dur-
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Fig. 7. Distribution of pathological stage of operated patients
per year (1993–2003).
ing the last 10 years7. These dramatic changes in the in-
cidence of prostatic carcinoma have also resulted in mi-
grations of clinical and pathological stage1.
In our operative material most operations are on pa-
tients in the age group 60–70, and this does not differ
from other European centres8. Unlike European stud-
ies, American studies show a lower age of operated pa-
tients (55–60 years)9.
In recent years there has been a considerable growth
in the number of radical prostatectomies, both at other
centers and here. A study from the USA shows a sub-
stantial increase in the number of radical prostatec-
tomies in relation to other treatment options10, a study
from Hamburg, based on 1000 operated patients, shows
an increase of 225% from 1992–199811,12. We also ob-
served a significant increase, from 8 patients operated
on in 1993 to 130 in 2002.
In the last few years, our patients do not have high
PSA values so often, the median is the same, and PSA
values<10 ng/ml have risen continuously since 1999.
Similar results can be seen in a study by Winkler et
al.13, where patients with PSA levels < 10 ng/ml in-
creased from 30% (1988–94) to 63% (2001–2002) whe-
reas patients with PSA values > 20 ng/ml decreased
from 38% to 7% in the same period.
As for clinical stage, up to mid 1997 there were no
substantial changes (p=0.7), and after that a significant
increase in T1c stage can be seen (p<0.01). Other stud-
ies, too, mention an increase in T1c stage. Stamey and
associates describe an increase in T1c stage from 10% in
1988 to 73% in 199614. An increase in T1c from 35%
(1988–1994) to 55% (1999–2000) is shown in a study
from Great Britain13.
Reduced usage of CT and bone scintigraphy in pros-
tatic carcinoma workup has resulted from the introduc-
tion of standards for preoperative diagnostics workup,
drown up by the German Urology Association. With
N. Zebi} et al.: Changes in Clinical and Pathological Stage in Prostatic Carcinoma Patients, Coll. Antropol. 29 (2005) 2: 593–598
596
TABLE 1
FREQUENCY OF DIAGNOSING OF AFFECTED LYMPH NODES RELATED TO PREOPERATIVE PSA VALUES
Op-Year PSA ng/ml) Total N+ (%)
1993 < 4 2 0
4–10 1 0
10.1–20 3 0
> 20 2 1 (50%)
1994 < 4 9 0 (0%)
4–10 14 1 (7.1%)
10.1–20 13 3 (23.1%)
> 20 18 6 (33.3%)
1995 < 4 9 0 (0%)
4–10 20 3 (15.0%)
10.1–20 22 1 (4.6%)
> 20 21 2 (9.5%)
1996 < 4 8 0 (0%)
4–10 23 0 (0%)
10.1–20 23 1 (4.4%)
> 20 13 3 (23.1%)
1997 < 4 3 0 (0%)
4–10 23 2(8.7%)
10.1–20 11 1 (9.1%)
> 20 4 1 (25.0%)
1998 < 4 4 1 (25.1%)
4–10 29 6 (20.7%)
10.1–20 23 5 (21.7%)
> 20 10 4 (40.0%)
Op-Year PSA ng/ml) Total N+(%)
1999 < 4 9 0 (0%)
4–10 35 3 (8.6%)
10.1–20 32 7 (21.9%)
> 20 11 3 (27.3%)
2000 < 4 5 0 (0%)
4–10 45 2 (4.4%)
10.1–20 24 2 (8.3%)
> 20 19 2 (10.5%)
2001 < 4 5 0 (0%)
4–10 56 7 (12.5%)
10.1–20 24 2 (8.3%)
> 20 22 8 (36.4%)
2002 < 4 10 1 (10.0%)
4–10 73 4 (5.5%)
10.1–20 31 4 (12.9%)
> 20 13 4 (30.8%)
2003 < 4 2 0 (0%)
4–10 45 1 (2.2%)
10.1–20 21 0 (0%)
> 20 7 0 (0%)
Total < 4 66 2 (3.0%)
4–10 364 29 (8.0%)
10.1–20 227 26 (11.5%)
> 20 140 34 (24.3%)
PSA – prostate specific antigen, Op-Year – year of operation, N+ – number of affected lymph nodes
TABLE 2
PSA VALUES OF PATIENTS WITH AND WITHOUT PREVIOUS
HORMONAL THERAPY
PSA ng/ml)
N Min Max X SD
No hormonotherapy 714 0.1 140 14.2 16.2
Hormonotherapy 87 0.1 135 19.8 24.1
PSA – prostate specific antigen, Min – minimum, Max – maximum
that, a trend of patients’ treatment of lower tumor stage
is shown.
The technique of prostate biopsy and the number of
biopsy samples has changed in the course of time with
an increase in both the number of samples taken and
the number of early detected tumors. Similar results are
described in other studies15,16, too.
Analysis of the facts gathered from biopsy samples
(especially tumor grading) shows two things:
¿ the number of patients who had a well differenti-
ated tumor grading (G1) in the preoperative diag-
nostic workup changed from 17 to 50%,
¿ from 1998 an increase in the number of patients
with low differentiated grading (G3) can be seen.
After introduction of the Gleason classification in
1997, the material in the database subsequently adapt-
ed to this classification. In our material, the changes in
the Gleason score that appeared in the course of the
years were statistically significant (p<0.01).
Our study shows a continuous increase in organ-con-
fined tumors from 1997 to 2003. On the other hand, ad-
vanced tumors continuously decrease, from 76% in 1997
to 66% in 2002.
In 1997 an unusually high percentage of advanced
tumors can be observed, explicable by change of the pa-
thologist and by the stricter pathological criteria cre-
ated in that period. The high number of T3a tumors dur-
ing the entire period is probably the result of a technical
error, through which tumor-positive edges, so called
»iatrogenic perforations of capsule», were incorrectly in-
terpreted as T3 tumors.
Other studies also describe migrations of pathologi-
cal stage.
The National Cancer Data Base, for example, shows
a growth of pT2 tumors by 20%, and a decline in pT1
and pT3 by 21% and 9%, in an investigation based on
350,000 cases from 198617–19. And a Hamburg study re-
ports a 25% increase in pT2 and a considerable decrease
in pT3 stages. The authors believe that the main reason
for the 25% increase in the number of patients with pT2
stage was the too careful preoperative selection of pa-
tients with DRE, PSA, TRUS and prostate biopsy11,12.
Similar results can be seen in a study of Hankey and
associates, where diagnosis of organ-confined disease
increased annually by 18.7% (1988–1992), followed by a
decline.
On the other hand, the incidence of metastatic dis-
ease decreased annually by 1.3% (1988–1992), and dur-
ing 1995 a decrease of 17.9% was registered. According
to these findings, the percentage of patients with or-
gan-confined disease who had a radical prostatectomy,
increased from 7% in 1983 to 32% in 199220.
Stamey and associates also speak of an increase in
the number of organ-confined tumors from 40 to 75%
and of a decrease in the incidence of positive surgical
margins from 65 to 62% per annum14.
In our series, inexplicably high oscillations of pa-
tients with positive lymph nodes can be noted in 1998
(24%) and in 2003 (1%).
Our study confirms migration of clinical and patho-
logical stage of patients suffering from prostatic carci-
noma in the period from 1993 to 2003 and confirms sim-
ilar migrations described in the USA, Germany and
other European countries. Stage migration is the result
of application of stricter diagnostic criteria, and of selec-
tion of patients by their referring urologists who direct
patients with different stages to different institutions.
Another cause for stage migration is the introduction of
S12C prostate biopsy at the end of 2001, which led to an
increase in the number of patients with lower tumor
stages.
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PROMJENE KLINI^KOG I PATOLO[KOG STADIJA U PACIJENATA SA KARCINOMOM PROSTATE,
KOD KOJIH JE U^INJENA RADIKALNA PROSTATEKTOMIJA U PERIODU IZME\U 1993. I 2003.
GODINE
S A @ E T A K
Cilj ovog rada je, da se na osnovi analize osobnog materijala relativno velikog broja pacijenata kojima je u~injena
radikalna retropubi~na ascedentna prostatektomija (RRP) ustanovi promjena stadija. U periodu izme|u 01.07.1993.
i 31.06.2003. na Urolo{koj klinici Kliniken-Essen-Mitte 801. pacijentu je u~injena RRP. Podaci o dijagnostici, lije~enju
i postoperativnom tijeku prikupljani su prospektivno u jednu bazu podataka. Analiziran je klini~ki i patolo{ki stadij
te broj pacijenata sa pozitivnim limfnim ~vorovima. Tijekom opservacijskog perioda do{lo je do zna~ajnog porasta
broja radikalnih prostatektomija, od 8 u 1993. do 130 u 2002. g. Broj organ ograni~enih tumora od 1997. do 2003. g je
tako|er u kontinuiranom porastu. Nasuprot tome, uznapredovali i metastatski tumori su u kontinuiranom padu od
76% u 1997. do 66% u 2002. g U periodu od 1994. do 2003. g. uo~ava se porast broja T1c tumora za 20%. Uvo|enjem
sistematske 12-cilindri~ne biopsije (S12C) detekcija karcinoma prostate se pove}ala za 38%, a tako|er je do{lo i do
pove}anja broja dijagnosticiranih tumora ni`eg klini~kog stadija. Ovi podaci potvr|uju trend migracije klini~kog i
patolo{kog stadija koji je nastao kao posljedica opse`nije uporabe PSA i S12C biopsije u dijagnostici karcinoma pros-
tate.
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